Australia's most trusted
source of pharma news
Posted 26 November 2024 AM
A huge Australian-led study has demonstrated for the first time that GLP-1 receptor agonists have significant benefits for kidney disease in people both with and without diabetes, leading to calls for improved access to the drugs.
The study, published in The Lancet Diabetes & Endocrinology, found that GLP-1 RAs reduce the risk of kidney failure by 16 per cent and the worsening of kidney function by 22 per cent compared to a placebo. The combined reduction in the risk of kidney failure, worsening kidney function, and death due to kidney disease was 19 per cent.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.